CellX Biosolutions AG

CellX Biosolutions is an innovative firm focused on bioremediation solutions, utilizing specially selected bacteria to effectively degrade harmful chemicals and address critical environmental challenges. Founded in 2024 and headquartered in Zurich, Switzerland, CellX Biosolutions specializes in developing microbial technologies for environmental remediation. The company raised CHF 1. 7 million in pre-seed funding on February 24, 2025, led by Positron Ventures with support from Kickfund and Venture Kick.

CellX Biosolutions specializes in innovative bioremediation solutions by harnessing the capabilities of specially selected bacteria for the degradation of harmful chemicals. Their core offerings focus on addressing significant environmental challenges such as the disposal of PFAS (per- and polyfluoroalkyl substances), pharmaceuticals, and microplastics. The company employs advanced microbial technology to evaluate and enhance the natural biodegradability of various chemical compounds, ultimately providing sustainable alternatives to traditional pollutant disposal methods. CellX's products are designed for a diverse clientele, including industries that generate chemical waste, pharmaceutical manufacturers, and environmental agencies across Europe and North America.

The end users of these solutions benefit from reduced environmental impact and compliance with stringent regulatory requirements. CellX Biosolutions generates revenue through a combination of service contracts and partnerships with industrial clients focused on waste management and environmental sustainability. Their business model typically involves direct collaboration with companies needing tailored solutions to chemical waste issues, where clients may engage in service agreements for biodegradation assessments and custom bacterial community development. Pricing structures for these services are established based on the complexity and scale of the waste treatment needed, often involving multi-year contracts that ensure ongoing support and optimization of bioremediation efforts.

Their flagship technology includes proprietary microfluidic devices used in field deployments, which facilitate the effective sampling and cultivation of bacteria for specific environmental applications. In February 2025, CellX Biosolutions raised CHF 1. 7 million in pre-seed funding led by Positron Ventures. The company will utilize this funding to bring its bacterial treatment solutions for PFAS to market and to accelerate its partnership with chemical producers on sustainable chemical waste treatment.

Plans include launching new products specifically designed for PFAS remediation and expanding into North American and European markets by late 2025.